Medicare Part B Premium Reduction In 2023 Has Reserves Built In If Lecanemab Launches
Executive Summary
But premiums in future years made need to keep pace with accelerating Medicare spending on Alzheimer’s drugs.
You may also be interested in...
CMS Expects 'Consistent' Coverage Of Amyloid PET Scans Even Without National Standard
Medicare has finally rescinded its 10-year-old national restrictions on covering the diagnostic now that advances in amyloid plaque-removing drugs have underscored the importance of PET scans.
Medicare Coverage Of Amyloid PET Scans In Alzheimer’s Expected To Be ‘Consistent,’ Even Without National Standard, CMS Says
Medicare has finally rescinded its 10-year-old national restrictions on covering the diagnostic now that advances in amyloid plaque-removing drugs have underscored the importance of PET scans.
Lecanemab And Medicare: Could Better FDA/CMS Communication Improve Coverage Chances?
Eisai/Biogen’s promising Phase III data fueling the companies’ hopes that Medicare will relax coverage restrictions for their Alzheimer’s treatment candidate. If the sponsors fail to change the NCD, lecanemab will need to rely on a registry for reimbursement after full approval.